Oncoral Pharma ApS gets an Innobooster grant
September 21, 2016
The Danish Innovation Fund has granted Oncoral Pharma ApS 497.310 DKK as an Innobooster grant to support an open label phase I study to show that their proprietary oral irinotecan tablet product can be taken together with oral capecitabine tablet as a new, safe and effective tablet based treatment to be taken at home.
Recent news
- Updated Manufacturing and Importation Authorisation February 13, 2018
- Solural Pharma gets a European patent August 9, 2017
- Ascelia Pharma AB acquires Oncoral Pharma ApS June 30, 2017
Contact us
- Energivej 42, DK 2750 Ballerup, Copenhagen, Denmark
- info@soluralpharma.com
- Find us on map